SEATTLE, WA and SAN FRANCISCO, CA--(Marketwire - October 27, 2008) - Targeted Genetics Corporation (NASDAQ: TGEN) announced positive results of its now completed Phase 1/2 clinical study with the last subject having finished the protocol-required follow-up. The data demonstrated that tgAAC94, an investigational agent designed to inhibit activity of tumor necrosis factor-alpha (TNF-alpha), a key mediator of inflammation, is well tolerated and may improve disease symptoms in inflammatory arthritis patients.